NasdaqGM - Delayed Quote USD

LeMaitre Vascular, Inc. (LMAT)

Compare
88.39 -0.66 (-0.74%)
At close: October 31 at 4:00 PM EDT
Loading Chart for LMAT
DELL
  • Previous Close 89.05
  • Open 88.41
  • Bid 63.08 x 200
  • Ask 112.66 x 200
  • Day's Range 86.61 - 89.30
  • 52 Week Range 47.33 - 93.32
  • Volume 191,950
  • Avg. Volume 110,754
  • Market Cap (intraday) 1.986B
  • Beta (5Y Monthly) 0.88
  • PE Ratio (TTM) 52.93
  • EPS (TTM) 1.67
  • Earnings Date Oct 31, 2024
  • Forward Dividend & Yield 0.64 (0.72%)
  • Ex-Dividend Date Aug 15, 2024
  • 1y Target Est 96.33

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.

www.lemaitre.com

614

Full Time Employees

December 31

Fiscal Year Ends

Recent News: LMAT

View More

Performance Overview: LMAT

Trailing total returns as of 10/31/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

LMAT
56.73%
S&P 500
19.62%

1-Year Return

LMAT
86.22%
S&P 500
36.93%

3-Year Return

LMAT
75.00%
S&P 500
23.89%

5-Year Return

LMAT
160.34%
S&P 500
87.26%

Compare To: LMAT

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: LMAT

View More

Valuation Measures

Annual
As of 10/31/2024
  • Market Cap

    1.99B

  • Enterprise Value

    1.89B

  • Trailing P/E

    52.93

  • Forward P/E

    42.92

  • PEG Ratio (5yr expected)

    2.09

  • Price/Sales (ttm)

    9.70

  • Price/Book (mrq)

    6.22

  • Enterprise Value/Revenue

    9.20

  • Enterprise Value/EBITDA

    32.88

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    18.33%

  • Return on Assets (ttm)

    8.27%

  • Return on Equity (ttm)

    12.49%

  • Revenue (ttm)

    205.62M

  • Net Income Avi to Common (ttm)

    37.68M

  • Diluted EPS (ttm)

    1.67

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    113.1M

  • Total Debt/Equity (mrq)

    5.76%

  • Levered Free Cash Flow (ttm)

    22.44M

Research Analysis: LMAT

View More

Earnings Per Share

Consensus EPS
 

Revenue vs. Earnings

Revenue 55.85M
Earnings 11.83M
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Analyst Price Targets

85.00 Low
96.33 Average
88.39 Current
105.00 High
 

Company Insights: LMAT

Research Reports: LMAT

View More
  • Raising target price to $95.00

    LEMAITRE VASCULAR INC has an Investment Rating of HOLD; a target price of $95.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.

    Rating
    Price Target
     
  • Lowering target price to $92.00

    LEMAITRE VASCULAR INC has an Investment Rating of HOLD; a target price of $92.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.

    Rating
    Price Target
     
  • Raising target price to $96.00

    LEMAITRE VASCULAR INC has an Investment Rating of HOLD; a target price of $96.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.

    Rating
    Price Target
     
  • What does Argus have to say about LMAT?

    LEMAITRE VASCULAR INC has an Investment Rating of HOLD; a target price of $95.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.

    Rating
    Price Target
     

People Also Watch